Multi-Gene Expression Test Helps Rule Out Thyroid Surgery In Large Study
This article was originally published in The Gray Sheet
Executive Summary
Presented and published study provides strong validation for use of Veracyte’s Afirma gene expression classifier in assessing patients with potential thyroid cancer.
You may also be interested in...
Utility Before Profitability: The Evolving Evidence Paradigm For Molecular Diagnostics
The standards needed for reimbursement of molecular diagnostics are changing – especially with respect to genomics-based tests, with their potential impact on public health with respect to screening, prevention, and measuring response to treatment, as well as cost. As the complexity of the assay development and launch process has grown, so too has the emphasis on evidence and clinical effectiveness, as well as the importance of finding better ways to align test coding and reimbursement with clinical value. But a lack of coordination across agencies and commercial players makes an assessment of the impact of any changes on evidence demands problematic.
Veracyte Meets New Medicare Coverage Mandate For Molecular Dx
Veracyte announced a positive coverage policy from Palmetto GBA Jan. 9 for its Afirma multi-gene expression classifier test, one of the first to go through the Medicare contractor’s new requirements.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.